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Abstract
Although diet is thought to affect the natural history of heart failure (HF), nutrient intake in HF patients has not been well studied. Based on
prior research linking high intake of Ca, Mg and K to improved cardiovascular health, we hypothesised that these nutrients would be inver-
sely associated with mortality in people with HF. Of the 161 808 participants in the Women’s Health Initiative (WHI), we studied 3340 who
experienced a HF hospitalisation. These participants were followed for post-hospitalisation all-cause mortality. Intake was assessed using
questionnaires on food and supplement intake. Hazard ratios (HR) and 95 % CI were calculated using Cox proportional hazards models
adjusted for demographics, physical function, co-morbidities and dietary covariates. Over a median of 4·6 years of follow-up, 1433 (42·9 %)
of the women died. HR across quartiles of dietary Ca intake were 1·00 (referent), 0·86 (95 % CI 0·73, 1·00), 0·88 (95 % CI 0·75, 1·04) and 0·92
(95 % CI 0·76, 1·11) (P for trend¼0·63). Corresponding HR were 1·00 (referent), 0·86 (95 % CI 0·71, 1·04), 0·88 (95 % CI 0·69, 1·11) and 0·84
(95 % CI 0·63, 1·12) (P for trend¼0·29), across quartiles of dietary Mg intake, and 1·00 (referent), 1·20 (95 % CI 1·01, 1·43), 1·06 (95 % CI
0·86, 1·32) and 1·16 (95 % CI 0·90, 1·51) (P for trend¼0·35), across quartiles of dietary K intake. Results were similar when total (dietary plus
supplemental) nutrient intakes were examined. In summary, among WHI participants with incident HF hospitalisation, intakes of Ca, Mg
and K were not significantly associated with subsequent mortality.
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Although diet is thought to affect the natural history of heart
failure (HF)(1), only a few studies have sought to determine
the effect of nutritional intake in patients with HF(2–7). Many
of these studies were small and examined the effect of dietary
supplements, rather than nutrient intake from food. The intake
of Ca, Mg and K could influence the course of HF through
effects on blood pressure, inflammation, endothelial function
and other pathways(8–16). In one small study, high-dose sup-
plementation with multiple micronutrients, including Ca and
Mg, improved left ventricular function and quality of life
among HF patients with reduced ejection fraction(6). However,
the effect of Ca, Mg and K intake on survival in patients with
HF is not known. We therefore examined the associations of
Ca, Mg and K intake from foods, as well as total intake from
diet and supplements, with all-cause mortality among
Women’s Health Initiative (WHI) participants who had a HF
hospitalisation. We hypothesised that higher intake of Ca,
Mg and K would be associated with lower rates of all-cause
mortality in women with HF.
Methods
Study population
The WHI has been previously described in depth(17,18).
Briefly, the WHI consisted of a clinical trial component with
68 132 post-menopausal women aged 50–79 years at the
study entry and an observational study component with
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93 676 post-menopausal women aged 50–79 years at the study
entry, recruited between 1993 and 1998 through forty clinical
centres. The WHI clinical trial included trials of hormone
therapy, dietary modification (DM) and Ca plus vitamin
D. The clinical trial and observational study were closed in
2004–05, and participants were invited to continue in the
WHI extension study, which started in 2005. For the present
analysis, we focused on the 4043 participants who had an
adjudicated hospitalisation for HF between study entry and
2005. HF hospitalisations were locally adjudicated with central
adjudication for quality control and were defined as hospital-
isations with a final diagnosis of HF accompanied by medical
treatment for HF, including diuretics, digitalis, vasodilators or
angiotensin-converting enzyme inhibitors. Supporting evi-
dence of HF from imaging was also noted. We excluded
twenty-nine participants who did not survive at least 1 d past
HF hospitalisation, 480 participants missing information on
Ca, Mg, K or covariates and 194 participants with implausible
energy intake (,2510 or .20 920 kJ/d) producing a final
sample size of 3340 women. The present study was conducted
according to the guidelines laid down in the Declaration of
Helsinki, and all procedures involving human subjects were
approved by the institutional review boards at all the partici-
pating centres. Written informed consent was obtained from
all the participants.
Nutrient intake
A modified block FFQ(19) was administered during a screening
visit for all the participants and additionally at year 1 for all
participants in the DM trial, yearly thereafter for a proportion
of the DM participants and at year 3 for the observational
study participants. The most recent diet assessment prior to
HF hospitalisation was selected for each participant. The
FFQ contained 122 questions about the frequency of con-
sumption of foods and beverages over the previous
3 months, nineteen adjustment items and four summary ques-
tions(19). The frequency questions included predefined
responses up to ‘2þ times per d’ for foods and ‘6þ times
per d’ for beverages. There were also questions on portion
sizes (small, medium or large), as compared with the specified
medium-size portion. Pictures were used to help with portion
size estimations.
Dietary nutrient intake was calculated by multiplying the
frequency of consumption of each food by the nutrient con-
tent for the specified portion size and then summing over
foods. Dietary nutrient intake was adjusted for energy intake
using the residuals method(20). To calculate total nutrient
intake, the nutrient intake from supplements was added to
the energy-adjusted dietary nutrient intake. In a study of the
measurement characteristics of the FFQ, deattenuated corre-
lation coefficients comparing 8 d of dietary intake (four 24-h
recalls and 4 d of diet records) with the FFQ were 0·73 for diet-
ary Ca, 0·78 for total Ca, 0·72 for dietary Mg, 0·69 for total Mg,
0·67 for total K and 0·67 for total K(19). The test–retest
intraclass correlation coefficient was 0·84 for Mg, and all
correlations were $0·67(19).
Covariates
Covariates were assessed by questionnaires and physical
measurement (blood pressure and height and weight used
to calculate BMI). As with the dietary assessment, the most
recent assessment of covariates prior to HF hospitalisation
was selected for each individual. For co-morbidities, such as
myocardial infarction and revascularisation, self-reported con-
ditions existing at the WHI baseline and occurring during the
WHI follow-up prior to HF hospitalisation were combined.
Mortality follow-up
The outcome of interest was all-cause mortality. Follow-up for
these analyses started on the date of HF hospitalisation and
continued through to the date of death or the last contact
with the participant prior to August 2009. Deaths were ascer-
tained by family, friends or health-care providers directly
reporting the death to the WHI; family, friends or the US
Postal Service responding to mailings; Internet searches (e.g.
obituary search engines); the social security death index; or
the National Death Index searches(21).
Statistical analysis
We summarised covariates using means for continuous vari-
ables and percentages for categorical variables by mortality
status. We calculated Pearson’s correlations among Ca, Mg
and K intakes. In the subset of women with FFQ completed
both before and after HF hospitalisation, we compared intakes
from pre- and post-HF questionnaires to assess diet stability.
Cox proportional hazards models were used to estimate the
hazard ratios and 95 % CI of mortality associated with quartiles
of the dietary intake of Ca, Mg and K as well as total intake
from diet and supplements. Model 1 adjusted for age at HF
hospitalisation (linear) and total energy intake (linear).
Model 2 further adjusted for race/ethnicity (white, black or
other), education (less than high school, high school graduate
including some college, college graduate or graduate school),
income (,$20 000, $20 000–34 999, $35 000–49 999 or
$$50 000), married (yes or no), current smoking (yes or
no), BMI (linear term), total exercise (metabolic equivalents
h/week, linear term), physical function score (linear term),
systolic blood pressure (linear term), diastolic blood pressure
(linear term), history of high cholesterol, high blood pressure,
diabetes, myocardial infarction, coronary revascularisation and
atrial fibrillation, use of off-study post-menopausal hormone
therapy, use of diuretics, b-blockers and angiotensin-convert-
ing enzyme inhibitors or angiotensin receptor blockers and
WHI study arm. Model 3 additionally adjusted for alcohol
intake (none, 0–10 g/d or .10 g/d) and quartiles of Na, Ca
(Mg and K models), Mg (Ca and K models), K (Ca and
Mg models), protein, saturated fat, monounsaturated fat,
polyunsaturated fat and fibre. Because intake of Ca, Mg
and K may reduce blood pressure, adjusting for factors
related to blood pressure may be an over-adjustment. We
therefore constructed a final model adjusted for all of the
factors in model 3, except for systolic and diastolic blood
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pressure, history of high blood pressure and use of diure-
tics, b-blockers and angiotensin-converting enzyme inhibi-
tors or angiotensin receptor blockers. Collinearity was
examined using the variance inflation factor. None of the
variance inflation factors exceeded 4·1, below the threshold
of 10, which has been proposed as an indicator of import-
ant collinearity(22). Tests for linear trend were performed by
including the median of each quartile as a continuous vari-
able in the models. Potentially non-linear associations were
explored using penalised splines(23).
In sensitivity analyses, we excluded participants with
self-reported HF at study entry because pre-existing HF may
alter diet (n 303), participants with a history of cancer at base-
line or during follow-up because of the cardiotoxic effects of
some chemotherapeutic agents (n 654) and participants in
the DM or Ca plus vitamin D trials because these participants
may have altered their intake in ways not fully captured by the
FFQ (n 1215). Finally, we excluded participants who did not
have a physician diagnosis of HF at the index hospitalisation,
because of the potential for misclassification of disease (n 251).
Table 1. Characteristics of 3340 Women’s Health Initiative (WHI) participants with heart failure hospitalisation
by mortality





Mean SD Mean SD
Age at heart failure hospitalisation (years) 73·8 6·7 71·9 7·2
Race/ethnicity (%)
American Indian/Alaskan native 0·8 0·3
Asian/Pacific Islander 1·3 0·6
Black 10·1 10·9
Hispanic 1·4 2·4
White not of Hispanic origin 85·6 84·8
Not one of above 0·9 1·0
Education (%)
Less than high school 9·1 8·3
High school graduate/some college 62·3 60·4
College graduate 8·2 8·3
Graduate school 20·5 22·9
Income (%)
, $20 000 36·0 28·3
$20 000–34 999 29·2 31·5
$35 000–49 999 17·6 17·7
$ $50 000 17·2 22·5
Married (%) 48·3 51·7
Current cigarette smoking (%) 24·2 21·1
BMI (kg/m2) 29·9 7·3 30·9 7·4
Physical activity (MET-h/week) 8·1 10·9 9·4 11·5
Physical function score 54·2 27·0 63·2 25·8
Systolic blood pressure (mmHg) 135 21 134 19
Diastolic blood pressure (mmHg) 71 11 73 11
History of high cholesterol (%) 24·2 21·1
History of hypertension (%) 59·6 57·4
History of diabetes (%) 31·6 25·2
History of myocardial infarction (%) 21·6 14·9
History of revascularisation (%) 18·7 16·1
History of atrial fibrillation (%) 16·9 12·8
Off-study post-menopausal hormone use (%) 22·2 29·0
Use of diuretics (%) 46·2 38·3
Use of b-blockers (%) 23·0 23·9
Use of ACE inhibitor or ARB (%) 33·5 30·9
Total energy (kJ/d) 6397 2648 6565 2536
Ca (mg/d) 802 346 807 330
Mg (mg/d) 247 54 248 53
K (mg/d) 2611 639 2598 622
WHI arm (%)
Oestrogen alone intervention 5·0 5·1
Oestrogen alone control 4·8 5·5
Oestrogen plus progestin intervention 4·3 4·8
Oestrogen plus progestin control 4·6 4·6
Diet modification intervention 10·7 12·6
Diet modification control 14·9 19·4
Ca/vitamin D intervention 8·6 11·5
Ca/vitamin D control 8·9 11·2
MET, metabolic equivalents; ACE, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers.
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We stratified results by whether the participants had a history of
IHD prior to the index HF hospitalisation (history of myocardial
infarction or revascularisation) and tested whether the associ-
ations between the micronutrients and mortality varied by
history of IHD by including the product of an indicator variable
for IHD and the median values of the micronutrient quartiles.
We tested the proportional hazards assumption by including
the product of micronutrients and the natural logarithm of
time as a term in the models; there was no evidence of vio-
lation of the proportional hazards assumption. Statistical ana-
lyses were conducted using SAS version 9.2 and R version
2.12.1. Two-sided P values ,0·05 were considered statistically
significant.
Results
Over a median of 4·6 years of follow-up (interquartile range
1·5–6·9 years) after HF hospitalisation, 1433 women died
(42·9 %). Characteristics of the study population are described
in Table 1. The women who died were older, had lower physi-
cal activity, were more likely to use diuretics, and were more
likely to have diabetes, hypertension, myocardial infarction,
coronary revascularisation and atrial fibrillation. Dietary Ca
intake was moderately correlated with dietary Mg (r 0·48)
and K (r 0·54). Dietary intake of Mg and K were highly corre-
lated (r 0·84). Among the 929 women with diet assessment
before and after HF hospitalisation, correlations between
Table 2. Calcium, magnesium and potassium from foods and survival among women with heart failure
(Hazard ratios (HR) and 95 % confidence intervals)
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P-trend
Ca
Median (mg/d) 476 655 833 1175
Deaths 373 346 341 373
Person-years 3589 4034 3884 3778
Model 1* 0·29
HR 1 0·82 0·82 0·89
95 % CI Referent 0·71, 0·95 0·71, 0·95 0·77, 1·03
Model 2† 0·79
HR 1 0·88 0·90 0·95
95 % CI Referent 0·76, 1·02 0·78, 1·05 0·82, 1·10
Model 3‡ 0·63
HR 1 0·86 0·88 0·92
95 % CI Referent 0·73, 1·00 0·75, 1·04 0·76, 1·11
Mg
Median (mg/d) 187 227 262 309
Deaths 370 343 364 356
Person-years 3721 3688 3845 4030
Model 1* 0·002
HR 1 0·88 0·87 0·79
95 % CI Referent 0·76, 1·01 0·75, 1·00 0·68, 0·91
Model 2† 0·09
HR 1 0·93 0·92 0·87
95 % CI Referent 0·80, 1·08 0·79, 1·07 0·75, 1·02
Model 3‡ 0·29
HR 1 0·86 0·88 0·84
95 % CI Referent 0·71, 1·04 0·69, 1·11 0·63, 1·12
K
Median (mg/d) 1895 2360 2754 3325
Deaths 341 373 348 371
Person-years 3754 3582 3965 3982
Model 1* 0·03
HR 1 1·07 0·87 0·90
95 % CI Referent 0·93, 1·24 0·75, 1·02 0·78, 1·04
Model 2† 0·57
HR 1 1·11 0·95 1·00
95 % CI Referent 0·95, 1·29 0·81, 1·11 0·85, 1·17
Model 3‡ 0·35
HR 1 1·20 1·06 1·16
95 % CI Referent 1·01, 1·43 0·86, 1·32 0·90, 1·51
* Model 1 adjusted for age at heart failure hospitalisation (linear) and total energy intake (linear).
† Model 2 adjusted for variables in model 1 and race/ethnicity (white, black or other), education (less than high school,
high school graduate/some college, college graduate or graduate school), income (,$20 000, $20 000–34 999,
$35 000–49 999 or $$50 000), married (yes or no), current smoking (yes or no), BMI (linear term), total exercise
(metabolic equivalents h/week, linear term), physical function score (linear term), systolic blood pressure (linear
term), diastolic blood pressure (linear term), history of high cholesterol, high blood pressure, diabetes, myocardial
infarction, coronary revascularisation and atrial fibrillation, use of off-study post-menopausal hormone therapy, use of
diuretics, b-blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and Women’s
Health Initiative study arm.
‡ Model 3 adjusted for variables in model 2 and alcohol intake (none, 0–10 g/d or .10 g/d), and quartiles of Na, Ca
(Mg and K models), Mg (Ca and K models), K (Ca and Mg models), protein, saturated fat, monounsaturated fat, poly-
unsaturated fat and fibre.
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pre- and post-HF hospitalisation nutrient intakes were moder-
ate (r 0·49 for Ca, 0·56 for Mg and 0·54 for K).
In age- and energy-adjusted models, dietary intake ofMg and K
were inversely associated with mortality (Table 2).However, after
further multivariable adjustment, there was no significant associ-
ation between any of the micronutrients and mortality. When
dietary Ca, Mg and K were considered as continuous variables
using penalised splines, there was no significant linear or non-
linear association. Total intake (from foods and supplements)
of Ca, Mg and K was associated with mortality in age- and
energy-adjusted models, but the associations were not evident
after multivariable adjustment (Table 3). The findings were the
same when we did not adjust for blood pressure-related vari-
ables. Results after excluding participants with baseline self-
reported HF, participants with a history of cancer, participants
in the DM or Ca plus vitamin D trials or participants who did
not have a physician diagnosis of HF at the index hospitalisation
were not materially different. No significant associations of Ca,
Mg or K with mortality were observed among the women with
a history of IHD (n 860) or those without a history of IHD (n
2480), and tests for interaction between the nutrients and history
of IHD were not statistically significant.
Table 3. Calcium, magnesium and potassium from foods and supplements and survival
among women with heart failure
(Hazard ratios (HR) and 95 % confidence intervals)
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P-trend
Ca
Median (mg/d) 555 830 1206 1844
Deaths 357 367 367 342
Person-years 3802 3649 3725 4108
Model 1* 0·002
HR 1 1·00 0·96 0·80
95 % CI Referent 0·86, 1·15 0·83, 1·11 0·69, 0·93
Model 2† 0·17
HR 1 1·07 1·07 0·92
95 % CI Referent 0·92, 1·25 0·92, 1·24 0·78, 1·08
Model 3‡ 0·16
HR 1 1·08 1·07 0·91
95 % CI Referent 0·93, 1·26 0·91, 1·26 0·77, 1·09
Mg
Median (mg/d) 199 259 320 408
Deaths 350 354 373 356
Person-years 3725 3784 3748 4027
Model 1* 0·03
HR 1 0·91 0·94 0·84
95 % CI Referent 0·79, 1·06 0·82, 1·09 0·72, 0·97
Model 2† 0·98
HR 1 0·99 1·07 0·98
95 % CI Referent 0·85, 1·15 0·92, 1·25 0·84, 1·15
Model 3‡ 0·46
HR 1 1·05 1·12 1·07
95 % CI Referent 0·89, 1·24 0·94, 1·32 0·88, 1·30
K
Median (mg/d) 1907 2378 2771 3346
Deaths 342 377 346 368
Person-years 3762 3566 3952 4005
Model 1* 0·02
HR 1 1·09 0·87 0·89
95 % CI Referent 0·95, 1·27 0·75, 1·01 0·77, 1·03
Model 2† 0·47
HR 1 1·14 0·94 1·00
95 % CI Referent 0·98, 1·32 0·81, 1·10 0·85, 1·17
Model 3‡ 0·51
HR 1 1·23 1·04 1·14
95 % CI Referent 1·03, 1·46 0·84, 1·29 0·88, 1·47
* Model 1 adjusted for age at heart failure hospitalisation (linear) and total energy intake (linear).
† Model 2 adjusted for variables in model 1 and race/ethnicity (white, black or other), education (less
than high school, high school graduate/some college, college graduate or graduate school), income
(,$20 000, $20 000–34 999, $35 000–49 999 or $$50 000), married (yes or no), current smoking
(yes or no), BMI (linear term), total exercise (metabolic equivalents h/week, linear term), physical
function score (linear term), systolic blood pressure (linear term), diastolic blood pressure (linear
term), history of high cholesterol, high blood pressure, diabetes, myocardial infarction, coronary
revascularisation and atrial fibrillation, use of off-study post-menopausal hormone therapy, use of
diuretics, b-blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers
and Women’s Health Initiative study arm.
‡ Model 3 adjusted for variables in model 2 and alcohol intake (none, 0–10 g/d or .10 g/d), and quar-
tiles of Na, Ca (Mg and K models), Mg (Ca and K models), K (Ca and Mg models), protein, saturated
fat, monounsaturated fat, polyunsaturated fat and fibre.
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Discussion
We did not find significant associations between dietary or total
intake of Ca, Mg and K and mortality in WHI participants with
HF. We had hypothesised that these nutrients would be associ-
ated with mortality based on previous research on HF and other
CVD. For example, supplementation with Ca, Mg and K may
reduce blood pressure, a risk factor for HF(11–14). Extremely
low Ca levels can cause HF in rare instances(24). However, Ca
supplements have been associated with increased risk of myo-
cardial infarction and stroke in some studies(16). High dietary
intake of Mg has been inversely associated with the develop-
ment of hypertension and type 2 diabetes(25,26), risk factors for
HF and with markers of inflammation and endothelial func-
tion(9,10). Patients with HF are more likely to have low serum
Mg than other older individuals, and low serum Mg has been
associated with all-cause mortality in HF patients(27,28). Higher
K excretion, which in part reflects greater intake, is associated
with a lower rate of CVD(15). Low serum K has been associated
with mortality in the context of HF(29,30). In addition, diet pat-
terns and foods with high Ca, Mg and K content have been
associated with incident HF(31–34).
There are a number of potential explanations for the lack of
associations observed in the present study. The present
hypothesis that intake of Ca, Mg and K are associated with
all-cause mortality in women with HF relied on the assump-
tion that availability of these nutrients in the body is related
to dietary consumption. HF patients are often aggressively
treated with multiple medications, which could confound or
mask any influence of diet. Diuretics, which are a mainstay
of HF treatment, can directly make an impact on circulating
levels of K and Mg through urinary excretion(35). We did not
have data to examine how dietary intake influences serum
levels of Ca, Mg and K in the present population. Prior to
HF hospitalisation, 42 % of the population were treated with
diuretics. The use of diuretics could weaken the relationship
between intake of the micronutrients and the effective
exposure to them. In fact, the women who died following
hospitalisation for HF were more likely to have hypertension
and to use diuretics. We adjusted for diuretic use and other
medication use prior to hospitalisation, but we were not
able to capture medication use following hospitalisation.
Additionally, kidney dysfunction is very common in HF and
may influence the retention and availability of Ca, Mg and
K. We did not have measures of kidney function in the present
population.
The present dietary assessment was not ideal. FFQ are known
to have substantial errors, which reduces the power to detect
modest effects of diet. In addition, we used dietary assessment
prior to HF hospitalisation rather than dietary assessment at the
time of HF hospitalisation, and the correlations between pre-
and post-HF hospitalisation intake of nutrients were moderate.
This could lead to misclassification of diet during the relevant
time period, biasing results towards no association if the mis-
classification is not related to mortality. However, in the present
study, the errors in exposure assessment may be related to mor-
tality, and the resulting bias would depend on the relationship
between the error and underlying likelihood of death. We were
not able to rule out unmeasured or residual confounding, for
example, by severity of HF or kidney function, which were not
assessed. We did not have information on left ventricular systolic
function or adjudicated HF aetiology; the relationship between
diet and mortality in patients with HF could plausibly differ by
these characteristics. We did examine the relationship between
the micronutrients and mortality in women with and without evi-
dence of ischaemic disease prior to HF hospitalisation, and we
did not find associations of Ca, Mg or K in women with or without
history of IHD. Finally, dietary intake of these nutrients, rather
than serum levels, simply may not affect mortality in HF patients.
In addition to the limitations of the present study, there were
important strengths. These included the racially and ethnically
diverse population, the extensive information collected on the
WHI participants, the large number of HF hospitalisations
among these participants and the relatively long follow-up for
post-HF hospitalisation mortality.
In summary, we did not find significant associations
between intake of Ca, Mg or K and post-HF hospitalisation
mortality in WHI participants. These results do not challenge
the present dietary recommendation for HF patients. Further
research is needed to conclusively determine whether nutrient
intake can reduce mortality in HF patients.
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